ELF is running a pilot with a company to see if we can help recruit individuals for ongoing clinical trials in Europe in different respiratory disease areas.
The company is currently recruiting patients with advanced lung cancer in Spain and Poland into a clinical trial. The trial is testing a new immunotherapy drug called MGD019. It will look at whether the drug is effective for certain tumour types including advanced non-small cell lung cancer. The researchers hope that certain tumour types will be sensitive to the new treatment. The trial will also test the safety of the new drug. It will do this for example by carrying out blood tests with participants to make sure it is not having a detrimental effect on their immune system.
If you live in Spain or Poland, have advanced non-small cell lung cancer and would like to find out more about the trial, you can do so here:
Learn more about ELF’s pilot initiative to help recruit patients into clinical trials: https://europeanlung.org/en/news-and-blog/getting-involved-in-clinical-trials/
Sign up to our free monthly newsletter to get the latest information and research news on lung conditions, plus views from experts and patients! You can unsubscribe at any time.
ELF is a non-profit organisation registered as a UK company (VAT no. GB 115 0027 74) and charity (no. 1118930).
Our Brussels office enterprise number is 0738.383.695
European Lung Foundation's TR ID number in the Transparency Register is: 094039644810-79
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.